Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Double Blind Phase	STARTED	Octreotide+ Everolimus	216
Double Blind Phase	STARTED	Octreotide+ Placebo Followed by Open Label Arm	213
Double Blind Phase	Safety Set	Octreotide+ Everolimus	215
Double Blind Phase	Safety Set	Octreotide+ Placebo Followed by Open Label Arm	211
Double Blind Phase	COMPLETED	Octreotide+ Everolimus	0
Double Blind Phase	COMPLETED	Octreotide+ Placebo Followed by Open Label Arm	0
Double Blind Phase	NOT COMPLETED	Octreotide+ Everolimus	216
Double Blind Phase	NOT COMPLETED	Octreotide+ Placebo Followed by Open Label Arm	213
Open Label Phase	STARTED	Octreotide+ Everolimus	0
Open Label Phase	STARTED	Octreotide+ Placebo Followed by Open Label Arm	170
Open Label Phase	COMPLETED	Octreotide+ Everolimus	0
Open Label Phase	COMPLETED	Octreotide+ Placebo Followed by Open Label Arm	0
Open Label Phase	NOT COMPLETED	Octreotide+ Everolimus	0
Open Label Phase	NOT COMPLETED	Octreotide+ Placebo Followed by Open Label Arm	170

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00412061/flow